Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
PharmacoEconomics · 2024-06 · 42 (6) · 679-691
DOI: 10.1007/s40273-024-01371-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics, online erschienen am 07.04.2024. Verfasst von Anna Kenseth und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cost-Benefit Analysis, Quality-Adjusted Life Years, Deep Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Norwegian Research Council.
Abstract (Originalsprache)
OBJECTIVES: Accurate risk stratification of patients with stage II and III colorectal cancer (CRC) prior to treatment selection enables limited health resources to be efficiently allocated to patients who are likely to benefit from adjuvant chemotherapy. We aimed to investigate the cost-effectiveness of a recently developed deep learning-based prognostic method, Histotyping, from the perspective of the Norwegian healthcare system. METHODS: Two partitioned survival models were developed to assess the cost-effectiveness of Histotyping for two treatment cohorts: patients with CRC stage II and III. For each of the two cohorts, Histotyping was used for risk stratification to assign adjuvant chemotherapy and was compared with the standard of care (SOC) (adjuvant chemotherapy to all patients). Health outcomes measured in the model were quality-adjusted life years (QALYs) and life years (LYs) gained. Deterministic and probabilistic sensitivity analyses were performed to determine the impact of uncertainty. Scenario analyses were performed to assess the impact of the parameters with the greatest uncertainty. RESULTS: Risk-stratifying patients with CRC stage II and III using Histotyping was dominant (less costly and more effective) compared to SOC. In patients with CRC stage II, the net monetary benefit of Histotyping was 270,934 Norwegian kroners (NOK) (year of valuation is 2021), and the net health benefit of Histotyping was 0.99. In stage III, the net monetary benefit of Histotyping was 195,419 NOK, and the net health benefit of Histotyping was 0.71. CONCLUSIONS: Risk-stratifying patients with CRC using Histotyping prior to the administration of adjuvant chemotherapy is likely to be a cost-effective strategy in Norway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ks2024@cam.ac.uk.
- Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. ks2024@cam.ac.uk.
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom. ks2024@cam.ac.uk.
- Department of Health Management and Health Economics, Institute of Health and Society,, University of Oslo, Oslo, Norway.
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
ORCID-Profile: Mikyung Kelly Seo
Förderung
- Norwegian Research Council
Zitieren
APA
Kenseth, A., Kantorova, D., Seo, M. K., Aas, E., Cairns, J., Kerr, D., Askautrud, H., & Jacobsen, J. E. (2024). Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?. PharmacoEconomics, 42(6), 679-691. https://doi.org/10.1007/s40273-024-01371-1
Vancouver
Kenseth A, Kantorova D, Seo MK, Aas E, Cairns J, Kerr D, et al. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?. PharmacoEconomics. 2024;42(6):679-691. doi:10.1007/s40273-024-01371-1
BibTeX
@article{Kenseth2024,
author = {Kenseth, Anna and Kantorova, Dominika and Seo, Mikyung Kelly and Aas, Eline and Cairns, John and Kerr, David and Askautrud, Hanne and Jacobsen, Jørn Evert},
title = {Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?},
journal = {PharmacoEconomics},
year = {2024},
volume = {42},
number = {6},
pages = {679--691},
doi = {10.1007/s40273-024-01371-1}
}
EUVIMED